SRR934854
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 104.27069645203679
- age_years
- 46
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.438
- MITOTIC_SPINDLE+0.410
- NOTCH_SIGNALING+0.395
- INTERFERON_ALPHA_RESPONSE+0.386
- PROTEIN_SECRETION+0.372
- INTERFERON_GAMMA_RESPONSE+0.342
- IL6_JAK_STAT3_SIGNALING+0.307
- ANDROGEN_RESPONSE+0.251
- BILE_ACID_METABOLISM+0.250
- IL2_STAT5_SIGNALING+0.239
Top 10 suppressed
- SPERMATOGENESIS-0.364
- KRAS_SIGNALING_DN-0.320
- PANCREAS_BETA_CELLS-0.300
- OXIDATIVE_PHOSPHORYLATION-0.266
- APICAL_SURFACE-0.165
- ANGIOGENESIS-0.112
- MYOGENESIS-0.089
- APICAL_JUNCTION-0.070
- ESTROGEN_RESPONSE_LATE-0.062
- HEDGEHOG_SIGNALING-0.057
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934942 | — | — | 0.914 |
| 2 | 6292335B-7CBB-45BE-AA2A-B39FFDA8768D | — | — | 0.896 |
| 3 | C1CCE12B-8892-49AB-8DF2-E5E280DEAE32 | — | — | 0.888 |
| 4 | SRR934946 | — | — | 0.886 |
| 5 | 8C34CD93-1AC0-4920-9E72-439EED0CF85D | — | — | 0.882 |
| 6 | SRR934833 | — | — | 0.881 |
| 7 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.880 |
| 8 | 385ECC71-2BF4-4E14-B2CC-8423E79BDEBE | — | — | 0.880 |
| 9 | SRR934776 | — | — | 0.875 |
| 10 | AD62B8A4-6AB8-4C99-80F5-98A1C085027D | — | — | 0.875 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.438 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.395 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.386 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.372 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.342 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.307 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.251 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.239 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.237 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.226 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.213 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.209 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.207 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.194 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.183 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.177 | Inavolisib | — uncovered |
| COMPLEMENT | 0.174 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.167 | Idelalisib | — uncovered |